Data gathered: October 17
Alternative Data for Alnylam Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 78 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 39,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 15 | Sign up | Sign up | Sign up |
| Patents | 354 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 276 | Sign up | Sign up | Sign up |
| Facebook Followers | 232 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,686 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,200 | Sign up | Sign up | Sign up |
| Twitter Followers | 17,201 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 2,460 | Sign up | Sign up | Sign up |
| News Mentions | 3 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 68 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,336 | Sign up | Sign up | Sign up |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
| Price | $296.75 |
| Target Price | Sign up |
| Volume | 1,110,000 |
| Market Cap | $36.9B |
| Year Range | $143.31 - $300.55 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
Leerink Partnrs Research Analysts Cut Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)October 17 - Biztoc.com |
 |
Scotiabank Begins Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY)October 16 - Biztoc.com |
 |
Cwm LLC Buys 3,272 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)October 16 - Biztoc.com |
 |
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $314.00October 16 - ETF Daily News |
|
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High After Analyst UpgradeOctober 15 - ETF Daily News |
|
830 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Park Avenue Securities LLCOctober 15 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 660M | 316M | 344M | -17M | 64M | -0.130 |
| Q1 '24 | 459M | 265M | 194M | -66M | -30M | -0.520 |
| Q4 '23 | 408M | 270M | 138M | -138M | -103M | -1.100 |
| Q3 '23 | 720M | 279M | 441M | 148M | 182M | 1.150 |
| Q2 '23 | 289M | 290M | -1.3M | -276M | -244M | -2.210 |
Insider Transactions View All
| Greenstreet Yvonne filed to sell 73,441 shares at $280. August 22 '24 |
| Fitzgerald Kevin Joseph filed to sell 12,881 shares at $274.7. August 14 '24 |
| Fitzgerald Kevin Joseph filed to sell 13,016 shares at $273.7. August 14 '24 |
| Fitzgerald Kevin Joseph filed to sell 33,485 shares at $268.7. August 14 '24 |
| Fitzgerald Kevin Joseph filed to sell 14,174 shares at $272.4. August 14 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
Feb 15, 24 | Buy | $1K - $15K |
| Joshua Gottheimer Democrat |
Feb 15, 24 | Sell | $1K - $15K |
| Joshua Gottheimer Democrat |
Jan 7, 24 | Sell | $1K - $15K |
Read more about Alnylam Pharmaceuticals (ALNY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Alnylam Pharmaceuticals?
The Market Cap of Alnylam Pharmaceuticals is $36.9B.
What is the current stock price of Alnylam Pharmaceuticals?
Currently, the price of one share of Alnylam Pharmaceuticals stock is $296.75.
How can I analyze the ALNY stock price chart for investment decisions?
The ALNY stock price chart above provides a comprehensive visual representation of Alnylam Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Alnylam Pharmaceuticals shares. Our platform offers an up-to-date ALNY stock price chart, along with technical data analysis and alternative data insights.
Does ALNY offer dividends to its shareholders?
As of our latest update, Alnylam Pharmaceuticals (ALNY) does not offer dividends to its shareholders. Investors interested in Alnylam Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Alnylam Pharmaceuticals?
Some of the similar stocks of Alnylam Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.